PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Arthritis Care Res (Hoboken). Author manuscript; available in PMC 2014 July 1.
Published in final edited form as:
PMCID: PMC3631448
NIHMSID: NIHMS429104

Initiation of Tumor Necrosis Factor Alpha (TNFα) antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases

Abstract

Objectives

We tested the hypothesis that initiation of TNFα antagonists reduced the risk of fractures compared to nonbiologic comparator in patients with autoimmune diseases.

Methods

Using four large administrative databases, we assembled retrospective cohorts of patients with autoimmune diseases who initiated either a TNFα antagonist or a nonbiologic medication. We identified 3 mutually exclusive disease groups: rheumatoid arthritis (RA); inflammatory bowel disease (IBD); and psoriasis, psoriatic arthritis or ankylosing spondylitis (PsO-PsA-AS). We used baseline covariate data to calculate propensity scores (PS) for each disease group and used Cox regression to calculate hazard ratios (HR) and 95% confidence intervals (95%CI). We compared the risk of combined hip, radius/ulna, humerus, or pelvic fractures between PS-matched cohorts of new users of TNFα antagonists and nonbiologic comparator.

Results

We identified 9,020, 2,014 and 2,663 new PS matched episodes of TNFα antagonist and nonbiologic comparator use in RA, IBD and PsO-PsA-AS cohorts, respectively. The risk of combined fractures was similar between new users of TNFα antagonists and nonbiologic comparators for each disease (HR: 1.17, 95%CI [0.91, 1.51]; HR: 1.49, 95%CI [0.72, 3.11]; and HR: 0.92, 95%CI [0.47, 1.82] for RA, IBD and PsO-PsA-AS, respectively). In RA, the risk of combined fractures was associated with an average daily dose of prednisone equivalents >10 mg/day at baseline compared with no glucocorticoid (HR: 1.54, 95%CI [1.03, 2.30]).

Conclusions

The risk of fractures did not differ between initiators of a biologic and a nonbiologic comparator for any disease studied. Among RA patients, use of >10mg/day of prednisone equivalents at baseline increased the fracture risk.

Introduction

Patients with autoimmune disease, particularly rheumatoid arthritis (RA), have a higher risk of fractures compared to the general population (14) due to enhanced local and generalized bone loss (3, 5). In RA, osteoporosis and increased risk of fractures are associated not only with conventional risk factors such as aging, menopause and low body mass index (6), but also with disease-related factors such as prolonged use of glucocorticoids, ambulatory dysfunction, and inflammation (1, 6, 7).

Human and animal studies have shown that inflammatory cytokines have a major effect on bone metabolism (8, 9). Tumor necrosis factor-α (TNFα) induces osteoclast formation and activity (10, 11), and down-regulates osteoblast activity (12), thereby increasing bone loss in primary osteoporosis (13). Accordingly, inhibition of TNFα might be expected to reduce the risk of fractures by preventing bone loss in patients with inflammatory disease. Information about the effect of TNFα antagonists on bone physiology in patients with autoimmune diseases is restricted to measures of markers of bone turnover and bone mass (14, 15). Treatment with TNFα antagonists has been reported to decrease markers of bone resorption and to increase markers of bone formation (1618). Furthermore, use of TNFα antagonists was associated with an increase in bone mass and/or attenuation of expected bone loss (17, 1921). In addition, improved disease control with TNFα antagonists could decrease the use of glucocorticoids, a well known risk factor for osteoporotic fractures (22). Despite these favorable effects of TNFα antagonists on bone turnover and bone density, the effect on fracture risk is unclear. If indeed TNFα antagonists protect against fractures compared to nonbiologic comparators, they could be prescribed preferentially to patients at high risk for fractures with autoimmune diseases (if there is no contraindication) to avoid future fracture burden. Thus, as part of a U.S. multi-institutional initiative, SABER (Safety Assessment of Biologic thERapy), we assembled a large retrospective cohort of patients with autoimmune diseases to assess the hypothesis that TNFα antagonists would reduce the risk of fractures compared to nonbiologic therapy in patients with autoimmune diseases.

Materials and Methods

Data source and study population

We studied a retrospective cohort of patients aged 18 years or older with study-defined autoimmune diseases using Tennessee’s Medicaid (TennCare, 1998–2005), Kaiser Permanente Northern California (KPNC, 1998–2007), New Jersey’s Pharmaceutical Assistance to the Age and Disabled and Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PAAD/PACE, 1998–2006), and the National Medicare and Medicaid (MAX/MED, 2000–2006 - excluding Tennessee) databases. This cohort was categorized into three mutually-exclusive groups using the earliest ICD-9 coded health care encounters within the year before cohort entry (baseline): 1) rheumatoid arthritis (RA; ICD9-CM codes: 714.**, except 714.3*), 2) inflammatory bowel disease (IBD; ICD9-CM codes: 556.*, 555.*), and 3) psoriasis, psoriatic arthritis, or ankylosing spondylitis (PsO-PsA-AS; ICD9-CM 696.0, 696.1,720.0). Patients were required to have 365 days of baseline information to ascertain other study selection criteria and covariates. Records missing gender information and patients with other autoimmune diseases that might warrant biologic and non-biologic treatment (e.g. juvenile rheumatoid arthritis, systemic lupus erythematosus) or with other serious diseases (Paget’s disease, organ transplant, HIV/AIDS, dialysis, cancer, liver or lung failure) were excluded. Patients entered the cohort on the date (t0) they filled the first prescription for the specific study regimen if they met the following criteria: continuous enrollment for at least 1 year before entering the cohort (≤30 days gaps were allowed) and no prescription for the study regimen filled during this period.

Episodes of exposure and exposure groups

To compare the risk of fractures between TNFα antagonists and nonbiologic comparator regimens, we first defined episodes of exposure. A new episode started on the date a first prescription for any of the study regimens was filled (t0), with no prescription filled for the same regimen during the year previous, and ended with the earliest of the following events: loss of enrollment, development of a serious disease (defined previously as exclusion criteria), death, end of the study, study outcome (first fracture), change in the medication regimen (e.g. filling a TNFα antagonist for nonbiologic users, or filling a different TNFα antagonist for biologic users - when comparing different TNFα antagonists), or 365 days without regimen medication available. We first identified episodes of TNFα antagonist use, and did not allow overlapping of person-time with other episodes. Within each episode of new use, we identified current use of each regimen, which extended from the start of the episode through the 30th day without medication available or the end of the episode, whichever occurred first. Only current use of study medication was included in the analyses.

We performed the following comparisons in each disease group:

  1. For patients with RA, in separate analyses, we compared the risk of fractures between:
    1. New TNFα antagonist (etanercept, infliximab or adalimumab) users versus new users of hydroxychloroquine and/or sulfasalazine and/or leflunomide (HCQ/SSZ/LEF) identified among patients who had used methotrexate during baseline.
    2. New users of specific TNFα antagonists (infliximab versus etanercept, infliximab versus adalimumab, and adalimumab versus etanercept).
  2. For patients with IBD we compared new users of infliximab or adalimumab (INF/ADA) versus new users of azathioprine or 6-mercaptopurine (AZA/6MP).
  3. For patients with PsO-PsA-AS we compared new users of TNFα antagonists versus new users of any nonbiologic comparator regimen (i.e. methotrexate and/or sulfasalazine and/or hydroxychloroquine and/or leflunomide).

Outcomes measure

The primary outcomes were: 1) a combined endpoint that included first hip, humerus, radius/ulna or pelvic fracture which are osteoporotic non-vertebral fractures that are accurately assessed in automated databases (23), 2) hip fracture alone. Due to a small number of events, the hip fracture endpoint was only evaluated among patients with RA. The secondary outcome for the RA cohort was the first clinical vertebral fracture. Fracture identification was performed using validated outcome algorithms for non-vertebral (23) and clinical vertebral fractures (24). We excluded fractures caused by major trauma and other conditions (see Supplement); and for clinical vertebral fractures, we excluded patients with a diagnosis/procedure compatible with vertebral fracture during baseline.

Covariates

Baseline covariates included demographic factors: age, gender, race (white/black/other), residence (urban/rural), nursing home (yes/no), calendar year; generic markers of comorbidity: number of hospitalizations, outpatient and emergency room visits, use of selected medications, chronic obstructive pulmonary disease, diabetes, modified Charlson-Deyo score (an adapted comorbidity index that uses administrative data instead of clinical variables) (25); surrogate markers of disease severity: extra-articular disease manifestations, number of intra-articular or orthopedic procedures, number of tests for inflammatory markers, use of non biologic disease-modifying antirheumatic drugs (DMARDs); and other known risk factors for fractures: previous fractures, diagnosis of osteoporosis, use of oral glucocorticoids (average daily dose in prednisone equivalents), nonsteroidal anti-inflammatory drugs, narcotics, sedative hypnotics, muscle relaxants, antidepressants, antipsychotics, use of drugs that affect bone metabolism (e.g. bisphosphonates, estrogens, thiazides). Baseline glucocorticoid exposure was calculated as the average of daily dose of prednisone equivalents in the 6 months preceding t0and categorized in four dose levels: none, less than 5 mg/day, 5–10 mg/day and >10 mg/day.

Statistical Analysis

In each dataset and disease group, a propensity score (PS) that included all baseline covariates above except oral glucocorticoids was calculated for each exposure episode using logistic regression models. This allowed control of potential confounders through PS greedy matching and assured that shared data were not individually identifiable. The variables and methodology for the creation of the PS have been described previously (26). The risk of fractures between disease specific PS-matched exposed groups was compared using Cox proportional hazard regression models and adjusted by baseline glucocorticoid use. Because patients could contribute ≥1 episodes of medication use, the Huber-White sandwich variance estimator was used to calculate robust standard errors for all hazard ratios (HR) and 95% confidence intervals [95%CI]. Planned subgroup analyses included stratification by age, previous fractures and baseline glucocorticoid use. The Tennessee’s Bureau of TennCare and the University’s Institutional Review Boards (IRB) of Vanderbilt, University of Alabama at Birmingham, Partners Healthcare, and Kaiser Foundation Research Institution approved the study protocol and waived consent requirements.

Results

As previously reported (27), the SABER cohort consisted of a total of 407,319 patients with an autoimmune disease who filled a study DMARD prescription and had complete baseline information. After excluding 170,788 (42%) patients with disease that did not meet study criteria or those with more than one study disease, we identified 139,611 patients with RA, 45,188 with IBD and 51,732 with PsO-PsA-AS. After selection criteria were applied we had 9,020, 2,014 and 2,663 PS-matched episodes of TNFα antagonists and comparator nonbiologic medications use in the RA, IBD and PsO-PsA-AS cohorts respectively (Figure 1).

Figure 1
Assembly of the retrospective cohort of patients with autoimmune disease. Episode is the observation time from the initiation to the end of follow-up

Rheumatoid arthritis

Baseline characteristics for both exposure groups were similar after PS-matching (Table 1). Patients with RA that started a new regimen were mainly white females with a median age of 58 years. The median follow-up period per episode was approximately 2 person-years. Baseline prednisone equivalents was not included in the PS matching, but was controlled for separately in our analyses. The use of >10 mg/day of prednisone equivalents at baseline was modestly higher in the TNFα antagonist users than the comparator group after PS matching. Of those using >10 mg/day of prednisone equivalents, 37% and 38% of nonbiologic and biologic users, respectively were using >15mg of prednisone equivalents daily, which is considered “high dose”. Although, by definition, all patients were prescribed methotrexate in the baseline year, approximately 51% of the patients in the HCQ/SSZ/LEF group and 38% in the TNFα antagonists group were a current user of methotrexate at t0. We found no differences in the incidence of hip fractures between exposure groups (Table 2, Figure 2). The survival curves for combined fractures, hip and clinical vertebral fractures were similar between both exposure groups (Figure 2A, 2B and 2C).

Figure 2
Time to event for fractures in patients with rheumatoid arthritis in propensity score matched cohorts, SABER 1998–2007
Table 1
Baseline characteristics for patients with rheumatoid arthritis, SABER 1998–2007
Table 2
Initiation of TNF-α antagonists and the risk of fractures in patients with autoimmune diseases after propensity score matching

We found no differences in the incidence of combined fractures when we compared different TNFα antagonists: infliximab versus etanercept (HR: 1.13, 95%CI [0.85, 1.49]); adalimumab versus infliximab (HR: 0.92, 95%CI [0.63, 1.35]); and adalimumab versus etanercept (HR: 0.89, 95%CI [0.63, 1.26]).

We observed a trend for increased risk of fractures with baseline glucocorticoid use in all the fracture groups studied. The association reached statistical significance for the combined fractures at >10 mg/day of prednisone equivalents compared to no use of glucocorticoids at baseline (HR: 1.54, 95%CI [1.03, 2.30]) (Table 3).

Table 3
Daily dose of prednisone equivalents at baseline and risk of fractures in patients with autoimmune disease

In subgroup analyses, the incidence of combined fractures was similar between exposure groups when stratified by age, previous fractures and baseline glucocorticoid use: ≤65 years old (HR: 1.39, 95%CI [0.91, 2.11]), ≤ 65 years old (HR: 1.06, 95%CI [0.79, 1.42], no previous fracture in the baseline period (HR: 1.20, 95%CI [0.93, 1.54]), history of previous fracture in the baseline period (HR: 0.90, 95%CI [0.25, 3.23]), use of ≤ 5 mg/day of prednisone equivalents at baseline (HR: 1.16, 95%CI [0.86, 1.57]), and use of >5 mg/day of prednisone equivalents at baseline (HR: 1.09, 95%CI [0.71, 1.69]).

Additional stratification by baseline glucocorticoid use indicated that >10 mg/day prednisone equivalents was associated with an increased risk of combined fractures among patients ≤65 years old (HR: 1.92, 95%CI [1.08, 3.39]), in those without previous fractures during the baseline period (HR: 1.57, 95% CI [1.05, 2.34]), and when compared to 5–10 mg/day of prednisone equivalents at baseline (HR: 1.57, 95%CI [1.01–2.42]) (Table 4). The risk of fractures was higher with higher doses of prednisone equivalents for the others subgroups studied (>65 years old, history of previous fractures), and when compared to those using <5 mg/day of daily dose of prednisone equivalents at baseline, but these association did not reach significance likely due to small number of episodes in these subgroups (Table 4).

Table 4
Risk of combined fractures and daily dose of prednisone equivalents at baseline in patients with rheumatoid arthritis in different subgroups

Inflammatory Bowel Disease

Baseline characteristics before and after matching by PS score are described in Supplement Table 2. Among patients with IBD, the incidence of combined fractures among new INF/ADA users was not significantly higher than new AZA/6-MP users (HR: 1.49, 95% CI [0.72, 3.11]) after adjusting for baseline glucocorticoid use (Table 2). In this disease group daily dose of prednisone equivalents at baseline was not associated with a statistically significant increased the risk of combined fractures when compared to no use (Table 3).

Psoriasis, psoriatic arthritis, and ankylosing spondylitis

Baseline characteristics before and after matching by PS score are described in Supplement Table 3. Among patients with PsO-PsA-AS, there were no differences in the risk of combined fractures between new TNFα antagonists users and new users of a nonbiologic comparator (HR: 0.92, 95%CI [0.47, 1.82]) after adjusting for baseline glucocorticoid use (Table 2). Similar to IBD, >10 mg/day of prednisone equivalents at baseline did not significantly increase the risk of combined fractures when compared to no use (Table 3).

Discussion

Our main finding is that fracture risk did not differ between initiators of a TNFα antagonist compared to a nonbiologic comparator regimen for any study disease (RA, IBD and PsO-PsA-AS). Notably, the risk of combined fractures was associated with higher daily doses of prednisone equivalents at baseline in RA patients.

Although some evidence indicates that treatment with TNFα antagonists may have positive effects on bone health in RA patients (16, 19, 21), we found no association between the initiation of TNFα antagonists and the occurrence of fractures. We also found that the risk of combined fractures was similar among the 3 different TNFα antagonists that we studied.

Most prior studies described the beneficial effects of TNFα antagonists on bone mineral density (BMD) and/or markers of bone turnover (16, 17, 21, 28, 29), but few tested this hypothesis in randomized placebo-controlled trials (20, 30, 31). Overall, the main finding of those studies was that treatment with TNFα antagonists resulted in arrest of bone loss at the hip and spine compared to baseline (19, 21, 28) or to other nonbiologic comparator regimens (16, 17), with less effects on bone loss in the metacarpals (20, 29, 30). However, in the Dutch BeSt trial, generalized BMD loss in the spine, hip and hands was similar among different treatment groups (including combination therapy with infliximab) after adjustment for baseline differences, and was associated with erosion progression (32). In the PREMIER trial, hand BMD loss was reduced in patients receiving the combination of adalimumab+methotrexate compared to methotrexate alone only in patients with high disease activity, but not in patients with low disease activity or in remission. Hand bone loss in the combination group was similar in patients with different disease activity and levels of loss were similar to those in patients in remission on methotrexate (31).

One study in female patients enrolled in the CORRONA (Consortium of Rheumatology Researchers of North America) registry, examined the fracture risk among different treatment regimens (33). In this study, monotherapy with a TNFα antagonist was associated with a decreased risk of overall fractures when compared with methotrexate monotherapy, but the expected differences in BMD were not observed. Instead, only the combination of methotrexate and other nonbiologic medication had a positive correlation with hip T score when compared with methotrexate monotherapy. Although this study included a large number of patients seen in clinical practice and used clinical covariates in the analysis, medication (exposure) groups were not clearly defined (33). Concordant with our findings, a recent study using data from a US commercially insured population and a Canadian Province found that the risk of fractures in RA patients did not differ among initiators of different regimens (including TNFα antagonists, methotrexate and other non biologic regimens) after adjusting by multiple clinical covariates(34).

Many studies have reported an increased risk of fractures at different anatomical sites with the use of glucocorticoids (22, 33, 35). We previously reported in this same cohort, that the initiation of both TNFα antagonists and other non biologic regimens were followed by a small reductions in the use of glucocorticoids (36). The percentage of patients taking glucocorticoids decreased less than 10% for new users of anti-TNF drugs and non biologic DMARDs 1 year after initiation of therapy (60.9 to 51.8% for anti-TNF users, 63.9 to 58.2% for LEF users, and 59.6 to 50.0% in HCQ/SSZ users). In the current study, we found an association between the use of >10 mg/d of prednisone equivalents at baseline and the risk of combined fractures, and that TNFα antagonists and other non biologic regimens had a similar risk of fractures at specific anatomic sites.

Our subgroup analyses suggest that >10 mg/day of prednisone equivalents at baseline was associated with an increased risk of combined fractures in patients ≤ 65 years old, and in those without previous fractures, compared to those with no use of baseline glucocorticoids. In the subgroup of patients >65 years old, and in those with history of previous fractures, the risk of fractures was also higher in those using >10 mg/day of prednisone equivalents at baseline, but did not reach statistical significance, probably due to the small sample size in each subgroup.

In the IBD and PsO-PsA-AS cohorts, we found that initiation of TNFα antagonists was not associated with a decrease in the risk of combined fractures. Few studies, with a small number of patients (3739) and without a control group (38, 40), have assessed the effect of infliximab treatment on BMD in patients with spondyloarthropathies. In general, these studies reported that treatment with infliximab increased the spine and hip BMD (3741). A post hoc and exploratory analysis of a randomized placebo-controlled trial in patients with AS reported that the median percent increase in spine and hip BMD score was higher in the infliximab treated group compared to placebo 24 weeks after treatment initiation (2.5% versus 0.5% in the spine, p<0.001; and 0.5% versus 0.2% at the hip, p<0.033) (18).

Despite the advantage of studying a large cohort of patients from real practice that allowed PS matching for multiple covariates, our study has several limitations: 1) we assumed that prescription fills represent medication use, but the actual use of study medications is unknown; 2) we relied on coded information to identify fractures which could have resulted in some misclassification, although we minimized outcome misclassification by using previously validated definitions; 3) clinical information is limited in these databases, so we relied on surrogate covariates to asses disease severity; 4) the study was not randomized and while we controlled for measured confounders through a PS matching method, major changes in time-dependent covariates could have unbalanced the study groups. Notably, this would be more likely to occur with outcomes that require long term exposures; 5) information related to lifetime cumulative doses of glucocorticoid, a risk factor for fractures (42), was not obtained. Instead, we used average daily dose of prednisone equivalents in the 6 months prior study entry in the analysis since some evidence suggested that average daily dose over a treatment period was more closely related to the risk of non-vertebral fractures than cumulative dose (35); 6) presence of unmeasured confounders (e.g.: BMD, physical activity, use of over the counter vitamin D and calcium supplements) that are balanced through randomization but not necessarily by PS matching could have biased our results; and 7) we had relatively short periods of follow-up that resulted in a relatively small number of events and limited our ability to detect small differences. Ideally, PsO, PsA, and AS would be analyzed separately since the clinical profile of these diseases are different. However, we aggregated data from these three seronegative spondyloarthropaties due to the small number of end points in each disease category. It is possible that TNFα antagonist users have less bone loss compared to nonbiologic users, but longer follow up time may be required to ascertain long term effects of specific therapies on fracture risk. For example, studies that examined the effects of antiresorptive drugs on the risk of osteoporotic fractures found evidence of protection in patients with pre-existing fractures and/or low BMD early in treatment (4346). However, there was little effect among those without pre-existing fractures and preserved BMD even after long follow-up periods when compared to placebo (47, 48). Thus, the effects of anti-TNF therapy may be most evident in patient populations with low BMD, or after extended follow up in an unselected population.

On the other hand, inflammation generates an array of inflammatory mediators that can activate osteoclasts through pathways that are independent of TNFα leading to bone resorption (49, 50). Thus, it is possible that inhibition of TNFα alone may not prevent increased bone loss, if there is ongoing inflammation.

In conclusion, we observed that the risk of fractures in patients with autoimmune diseases did not differ between new users of TNFα antagonists and a nonbiologic comparator medication, but was associated with >10 mg/day of prednisone equivalents among RA patients. The role of TNFα antagonists in bone health is still poorly defined. Studies of larger cohorts of patients with longer follow up are needed to determine if changes in bone density translate into changes in fracture risk. Currently, there is no clear evidence that suggests that TNFα antagonists are strongly associated with the risk of fractures.

Key messages

  • No association between risk of fractures and initiation of biologic therapy.
  • Risk of fractures associated with >10 mg/day of prednisone equivalents in RA.

Supplementary Material

Supp Table S1-S3

Acknowledgements

We are indebted to the Tennessee Bureau of TennCare of the Department of Finance and Administration, which provided the data on TennCare recipients On behalf of the SABER collaboration: Agency for Health-care Research and Quality (AHRQ), Parivash Nourjah; Brigham and Women’s Hospital, Robert Glynn, Mary Kowal, Joyce Lii, Jeremy Rassen, Sebastian Schneeweiss; Fallon Medical Center and University of Massachusetts, Leslie Harrold; Food and Drug Administration, David Graham, Carolyn McCloskey, Kristin Phucas; Kaiser Permanente Northern California; Kaiser Permanente Colorado, Marcia Raebel; University of Alabama at Birmingham, Nivedita Patkar, Kenneth Saag, Fenglong Xie; University of Pennsylvania, Kevin Haynes, James Lewis.

Funding statement: This work was supported by the Food and Drug Administration (FDA), the Agency for Healthcare Research and Quality (AHRQ) [U18 HSO17919-01, R01HS018517 to J.R.C.], the National Institutes of Health (NIH) [5T32GM007569-33 to V.K.K., AR053351 to J.R.C.,5P60AR56116 to C.G.G, C.M.S. and M.R.G], and Vanderbilt Physician Scientist Development Award (V.K.K).

Footnotes

Conflict of interest statement: JRC has received research support and consultant fees, from Abbott, Amgen, Centocor, Pfizer, BMS, Consortium of Rheumatology Researchers of North America (CORRONA), Roche/Genentech, and UCB. DHS has received research grants from Amgen, Lilly and Abbott and serves as a consultant to CORRONA. ED has received research support from Amgen. LH has received research support from Centocor, Genentech and Procter & Gamble. MG has received consultant fees from Rocky Mountain Poison and Drug Center funded by McNeil. The rest of authors have no conflict of interest to report.

Reference List

1. Weiss RJ, Wick MC, Ackermann PW, Montgomery SM. Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases -- a case-control study with 53,108 patients with fracture. J Rheumatol. 2010;37:2247–2250. [PubMed]
2. Huusko TM, Korpela M, Karppi P, Avikainen V, Kautiainen H, Sulkava R. Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. Ann Rheum Dis. 2001;60:521–522. [PMC free article] [PubMed]
3. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000;43:522–530. [PubMed]
4. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis. 1995;54:49–52. [PMC free article] [PubMed]
5. Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, et al. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12:R154. [PMC free article] [PubMed]
6. Hooyman JR, Melton LJ, III, Nelson AM, O'Fallon WM, Riggs BL. Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum. 1984;27:1353–1361. [PubMed]
7. Van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104–3112. [PubMed]
8. Agrawal M, Arora S, Li J, Rahmani R, Sun L, Steinlauf AF, et al. Bone, inflammation, and inflammatory bowel disease [review] Curr Osteoporos Rep. 2011;9:251–257. [PubMed]
9. Ding C, Parameswaran V, Udayan R, Burgess J, Jones G. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab. 2008;93:1952–1958. [PubMed]
10. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology. 2002;143:1108–1118. [PubMed]
11. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 2000;191:275–286. [PMC free article] [PubMed]
12. Gilbert L, He X, Farmer P, Boden S, Kozlowski M, Rubin J, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology. 2000;141:3956–3964. [PubMed]
13. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest. 2002;110:1419–1427. [PMC free article] [PubMed]
14. Barnabe C, Hanley DA. Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy [review] Semin Arthritis Rheum. 2009;39:116–122. [PubMed]
15. Veerappan SG, O'Morain CA, Daly JS, Ryan BM. Review article: the effects of antitumour necrosis factor-alpha on bone metabolism in inflammatory bowel disease [review] Aliment Pharmacol Ther. 2011;33:1261–1272. [PubMed]
16. Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther. 2007;9:R61. [PMC free article] [PubMed]
17. Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci. 2006;1069:420–427. [PubMed]
18. Visvanathan S, van der HD, Deodhar A, Wagner C, Baker DG, Han J, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:175–182. [PMC free article] [PubMed]
19. Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis. 2009;68:373–376. [PMC free article] [PubMed]
20. Haugeberg G, Conaghan PG, Quinn M, Emery P. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2009;68:1898–1901. [PubMed]
21. Lange U, Teichmann J, Muller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) 2005;44:1546–1548. [PubMed]
22. Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Kobashigawa T, et al. Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study. J Rheumatol. 2007;34:303–310. [PubMed]
23. Ray WA, Griffin MR, Fought RL, Adams ML. Identification of fractures from computerized Medicare files. J Clin Epidemiol. 1992;45:703–714. [PubMed]
24. Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG. Identification and validation of vertebral compression fractures using administrative claims data. Med Care. 2009;47:69–72. [PMC free article] [PubMed]
25. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619. [PubMed]
26. Herrinton LJ, Curtis JR, Chen L, Liu L, Delzell E, Lewis JD, et al. Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf. 2011;20:1199–1209. [PMC free article] [PubMed]
27. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306:2331–2339. [PMC free article] [PubMed]
28. Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:353–357. [PubMed]
29. Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1495–1499. [PMC free article] [PubMed]
30. Hoff M, Kvien TK, Kalvesten J, Elden A, Haugeberg G. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis. 2009;68:1171–1176. [PMC free article] [PubMed]
31. Hoff M, Kvien TK, Kalvesten J, Elden A, Kavanaugh A, Haugeberg G. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskelet Disord. 2011;12:54. [PMC free article] [PubMed]
32. Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Groenendael JH, Mallee C, et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:330–336. [PubMed]
33. Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 2009;15:155–160. [PubMed]
34. Kim SY, Schneeweiss S, Liu J, Solomon DH. Effects of disease-modifying antirheumatic drugs on non-vertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res. 2012;27:789–796. [PMC free article] [PubMed]
35. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000;39:1383–1389. [PubMed]
36. Kawai V, Grijalva CG, Arbogast P, Curtis JR, Solomon DH, Delzell E, et al. Changes in Cotherapies After Initiation of Disease-Modifying Antirheumatic Drug Therapy in Patients With Rheumatoid Arthritis. Arthritis Care Res. 2011;63:1415–1424. [PMC free article] [PubMed]
37. Mauro M, Radovic V, Armstrong D. Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients. Can J Gastroenterol. 2007;21:637–642. [PMC free article] [PubMed]
38. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol. 2005;100:2031–2035. [PubMed]
39. Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease. Ann N Y Acad Sci. 2006;1068:543–556. [PubMed]
40. Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with antitumour necrosis factor alpha. Ann Rheum Dis. 2003;62:347–349. [PMC free article] [PubMed]
41. Kang KY, Lee KY, Kwok SK, Ju JH, Park KS, Hong YS, et al. The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis. Joint Bone Spine. 2011;78:188–193. [PubMed]
42. de VF, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56:208–214. [PubMed]
43. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541. [PubMed]
44. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int. 1999;9:461–468. [PubMed]
45. McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res. 2004;19:728–736. [PubMed]
46. Masud T, McClung M, Geusens P. Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. Clin Interv Aging. 2009;4:445–449. [PMC free article] [PubMed]
47. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–2082. [PubMed]
48. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333–340. [PubMed]
49. Schett G, David JP. The multiple faces of autoimmune-mediated bone loss [review] Nat Rev Endocrinol. 2010;6:698–706. [PubMed]
50. Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention [review] Nat Rev Drug Discov. 2012;11:234–250. [PubMed]